CNBX PHARMACEUTICALS INC.
CNBX · Healthcare · $55396 mkt cap · FY2025 filings · Shallow moat ·
Doesn't clear the bar
The five investor questions
2022–2024: revenue 29958.00 to 130074.00, increasing; diluted EPS -3.59 to -0.02, increasing. Latest-filed diluted EPS remains usable for Business Trend, but an integer share-count change lacks enough evidence to confirm a comparable EPS basis; valuation growth therefore stays at 0%.
Median gross margin 100.0% over 2y, very stable.
Median ROIC -240.3%, above the 12% hurdle in 0% of years.
Net debt/EBITDA n/ax, interest coverage -7x.
Owner earnings trend unclear, share count growing (dilution).
Price vs. owner-earnings value range
- Owner earnings (normalized)
- —
- Value range / share
- —
- Conservative high estimate / share
- —
- Recent price
- $0.00
- Price vs. high estimate
- No price data
Conservative range under moat-index@2.0.0: low end 11.1×, high end capped at 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
21 years of fundamentals
The business, in plain English
It earned −154.1% on invested capital in FY2022, with a median of −240.3% across 5 filed years. The Returns on Capital filter above scores it 0/100.
CNBX's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.
The share count rose 40620.4% between FY2013 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.
Put together: Pricing Power is the strongest of the five filters (100/100) and Returns on Capital the weakest (0/100), which is how CNBX lands at 42/100 — a Shallow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in CNBX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Track record
How CNBX PHARMACEUTICALS INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
How to read this: each dot is what the engine would have scored CNBX on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the reconstructed history shown, CNBX did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.
Healthcare context
#317 of 737 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #315IART INTEGRA LIFESCIENCES HOLDINGS CORP42.4 out of 100, Shallow moatShallow moat
- #316CNMD CONMED CORPORATION42.3 out of 100, Shallow moatShallow moat
- #318KIDS OrthoPediatrics Corp42.3 out of 100, Shallow moatShallow moat
- #319CLDX Celldex Therapeutics, Inc.42.2 out of 100, Shallow moatShallow moat
Compare CNBX with its nearest peers →All Healthcare companies on the Index →
Common questions about CNBX
- Does CNBX PHARMACEUTICALS INC. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores CNBX PHARMACEUTICALS INC. (CNBX) 42.3 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 60, pricing power 100, returns on capital 0, balance-sheet safety 28, capital discipline 24.
- How has CNBX's Moat Score changed over time?
- The record logs 9 readings since Jul 17, 2026; the latest reads 42.3 out of 100 (shallow moat). No tier changes on record yet. (A methodology upgrade on Jul 20, 2026 re-based the score; readings across engine versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.